All right. Good afternoon, everyone, and welcome back to the 25th Annual Needham Healthcare Conference. My name is John Gionco. I'm a member of the Biopharma Research team here at Needham. For our next session, I'm excited to have Milestone Pharmaceuticals for a presentation followed by Q&A. It's my pleasure to introduce the company's CEO, Joseph Oliveto, and we will be joined by the company's CFO, Amit Hasija, as well as the company's CBO, Lorenz Muller, for the Q&A portion of today's session. Just before I turn it over for the presentation, I want to quickly inform our audience that if you'd like to submit questions, you may do so via the Q&A text box on the webcast player. With that, Joe, and team, it's great to have you here today. Thank you very much for joining us. Thank you, John. I, of course, want to thank all the colleagues at Needham, Serge included, for inviting us today. We really always look forward to participating in the Needham Conference. I also want to thank the audience members for spending the time to hear the Milestone update. Of course, we'll be making forward-looking statements today, and I'll direct all listeners to our 10-K, which we just filed last month, for a more fulsome disclosure of risk factors around the business. 2026 is really shaping up to be quite a transformative year for Milestone, really driven by the transformation of the company from a development stage company to a commercial company. Our product, etripamil or CARDAMYST, was approved. It was the first and only FDA-approved treatment for PSVT in more than 30 years. We received that approval in mid-December of last year. Following that approval, we were successful in having drug placed into the channel by the end of January and really launched the product in mid-February with sales representatives on the street. Also, 2026 will represent the start of our atrial fibrillation and rapid ventricular rate second indication for etripamil and the phase III development of that. We feel that AFib with RVR, as we call it, represents a very large addressable market, probably in the range of three to four times the target addressable market that we think about for PSVT. We also will be utilizing efficient regulatory pathway called the Supplemental NDA pathway or sNDA. The foundation for that is with the approval of CARDAMYST for SVT, we're enabling, or the FDA is enabling us to use that robust safety data set that we've generated for SVT and apply it, if you will, to the future indication of AFib with RVR. This enables the potential for us to get an approval utilizing a single phase three efficacy study, and we'll talk a little bit more about what that study looks like, as well as some of the data that we have to support the start of that study a little later in the presentation. Finally, on the finance side, the company did increase our balance sheet, at the end of 2025 and the early part of 2026. We feel like we're well-capitalized to launch etripamil or CARDAMYST in PSVT. We reported a pro forma cash and cash-equivalent number of $200 million. That was reported in March. It included $106 million on the balance sheet at the end of the year, plus an additional $94 million from subsequent financing events that occurred before that. The large portion of that was a $75 million royalty payment from RTW, our largest shareholder, and the owner of that royalty agreement that we have for CARDAMYST in PSVT for the U.S. Let me start by providing an outline from the patient point of view regarding PSVT. PSVT stands for paroxysmal supraventricular tachycardia. It's marked by episodes, or as patients often refer to them, attacks of an elevated heart rate. These attacks can be highly symptomatic, often including palpitations, chest pain or chest pressure, shortness of breath, sometimes lightheadedness. Nausea has been reported. really wanted to give the audience a feeling of what these patients are going through as their heart is racing at 160, 180, not uncommon to be above 200 beats per minute. The other aspect of these attacks is that they're unpredictable, meaning that patients are really not aware of when the attack will happen, how long it'll last, or even if it will be that attack with really symptomatic events, or if it'll be one with less symptomatic events when it occurs. The options available to these patients before CARDAMYST were really not that great. They involved the only approved drugs for the treatment of these events, and the breaking of the tachycardia and conversion to normal rhythm were via IV drugs, IV calcium channel blockers, IV adenosine, the latest drug, and these drugs are commonly delivered in the emergency department. Many patients describe to us both the combination of the unpredictability of the attacks combined with the symptomatology and the potential need to visit the emergency department as very anxiety-provoking, causing them to always be thinking about the condition even when they're actually not in an event. We hear words like, I feel like I'm walking on eggshells waiting for that next event. A little bit about PSVT from an epidemiology perspective. This slide presents, we believe that there's more than 2 million patients diagnosed in the United States with PSVT. It costs the healthcare system in excess of $5 billion annually, and you can see here some of the interventions and costs that really lead to that burden on the system. As I said, in December, CARDAMYST was approved. What's seen here is a picture of the product and the indication statement. CARDAMYST is a calcium channel blocker indicated for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. Really the whole concept from day one for developing this drug, and it was prospectively designed for this indication, was to attempt to deliver the efficacy that can be seen by the calcium channel blockers, again, already approved for PSVT, and deliver that efficacy in a safe, effective way at home such that the patient can treat themselves and empower themselves. A little bit more about the product is shown here. It is a portable on-demand nasal spray. That pack there that has two devices and two different doses of the drug fits in the pocket or the purse or the briefcase of the patient. It's easily accessible, has a nice long shelf life. The FDA approved the product with a robust clinical label that you can see. It is marked by a relatively fast onset of action. In our phase three pivotal trial, called Rapid itself, the drug started to show an effect with as early as five minutes, with about a third of the patients converting from tachycardia to normal rhythm within 10 minutes, half the patients converting within 17 minutes, that's the median time to conversion, and then about 64% of the patients converting within 30 minutes, which was the primary endpoint. That's compared to 31% in the placebo group. So twice as many patients converted within the half hour, the primary endpoint. They converted three times faster than the placebo. From the tolerability side, the drug was well-tolerated, with events greater than 5% being primarily in and around the nasal site of administration. So some nasal discomfort, some congestion, some watery eyes, some runny noses. Those are the events described in the product package insert. Again, we're very proud of this tolerability profile. Very importantly, what we did not see or saw very little evidence of was any reasonably large drop in blood pressure or too many reports of syncope, sort of in the range of 0.8% and 0.4%. That's less than 1% in either of those instances. Hopefully, the audience can, as you think about this condition and how I described it and how patients are, if you will, on edge each time they're thinking about when that next event's going to occur. Is it going to be the bad one? Is it going to be the one that I need to search out the emergency department? Hopefully, the audience can understand how having an at-the-ready medication with strong data and a reasonable chance of converting from tachycardia to normal rhythm without the disruption and reliance on the emergency department could lead to an empowerment for these patients. Really, we believe the commercial success of CARDAMYST is driven by an approach that appeals to all three stakeholder groups. For the patient, empowerment, that ability to take control over this condition or greater control over the condition than you otherwise would have now is really a key to our commercial success. We'll talk a little bit about how we make it easy to use and get for the patient, but foundational to its success is this idea of patient self-empowerment. For the prescribers, these prescribers, primarily cardiologists, right now are really trying to have their patients manage these events at home. The tools are not great for them, but if a patient can wait out and tolerate the symptoms long enough, they ask them to wait before they seek emergency department care. Really what etripamil does for these cardiologists and healthcare providers is give them a better tool to what they're already trying to do currently, which is manage the condition outside of the emergency department, or at least the events. We will lean into, and we think the success of this product is translated on a foundation of its mechanism. Cardiologists have been using calcium channel blockers for decades. It's a very trusted mechanism. When we present CARDAMYST to them, it's almost as if once they hear it's a calcium channel blocker in a nasal spray, they get the concept right out of the gate. They appreciate the robust clinical data that's in the package insert, and as a result of being in the field now with cardiologists and busy cardiology offices for a couple of months, we see the opportunity for them selfishly is to help free up some of their time of them and their nurses, as they're often fielding these calls from the patients as they're in the event. Not only is it helping the patient, it's really helping this very busy cardiology practice. Our whole goal to delivering CARDAMYST and this tool to their patients is also to enable them to make it easy to prescribe and for their patients to get it. Lastly, on the payer side, every new drug launch has to pay particular attention to satisfying the needs of payers. We feel we have the opportunity here to present a case where the patients, or I'm sorry, rather the payers, have really a very low need to want to manage this condition or manage this drug use. We'll talk a little bit more about this in the rest of the presentation, but really here, the foundation of this is still leaning into the medical need. These patients are in need. Their options available to them are not great when they're in event, and CARDAMYST solves that medical need or has potential to solve it from the view of the medical experts. However, an important aspect of this drug that most drugs do not have is the opportunity for significant cost offsets and a benefit to the system, if you will. That plays really well when we're in front of payers, and we've been in front of them for two years leading into the approval, and are now in active discussions with getting the drug covered so that it could benefit patients and healthcare providers. I'll talk about that in a little bit during the presentation as well. Why don't we move over to how we're going to access these healthcare providers and provide the details and supportive messages to them. What you see on this slide is a schematic representing the 2 million patients that we have uncovered as having a diagnosis of PSVT. What each of these individual stick figure represents is physicians that manage those patients. While there's 2 million patients with a diagnosis of SVT, about half of them, or 1 million, are actually in the healthcare system in any given year. If we think about 2026, we're expecting, based on the claims data and our market research, that about a million patients will be seen in the system that year. That ranges from everything from doctor's visits, emergency department visits, Holter monitors, et cetera. Those million patients are managed by about 400,000 healthcare providers, primarily cardiologists. Our goal for accessing a reasonable part of this market is to target those physicians that will be covering or treating about 500,000 or half a million patients in 2026. Those 500,000 patients are managed by 10,000 healthcare providers. You can see it broken down along the bottom here, about 8,000 clinical cardiologists, about 1,500 electrophysiologists. These are the key opinion leader experts in the area of rhythm disorders, and about 500 primary care physicians that are monikered that way, but really act like and manage like a cardiologist would. We feel we can get to these 10,000 healthcare providers with about 60 sales reps. We've launched with 60 sales representatives. Each sales representative has in the range of about 160 targets to be able to reach those 10,000 in total. Let me move over to the market access strategy. I mentioned this earlier before. The key for our strategy is really leaning into the understanding that no one, whether they be patients, healthcare providers, or payers, wants patients to be unnecessarily treated in the emergency department. This is for any patient that has already a diagnosis of SVT. We know what it is. They could recognize relatively easily that they're in an SVT event, and we'd like them not to be treated in the emergency department for somewhat obvious reasons. It's burdensome on everyone, the patient, the healthcare provider who's receiving those calls, or the payer that needs to pay for that three, four, or $5,000 emergency department visit. It's really not an efficient way to manage this condition. What's interesting, what we've also published on and recently published in, I believe it was in April or early April, is that about 24% of these emergency department visits where patients come in with a primary code of PSVT result in a hospital admission. This takes that three, four, or $5,000 emergency department visit to a $10,000+ overnight stay in the hospital. The clinical studies for etripamil in the phase III program, depending on what study you looked at, averaged about a 40% reduction in emergency department use. Our budget impact model, when we're presenting to payers, really leans into the fact that if we can reduce real-world utilization in the emergency department, we're saving those costs, we're saving those hospital admissions. It provides a nice cost offset, again, to supplement the medical need that the drug is able to provide for these patients. What would high-quality coverage mean for our patients and healthcare providers? I will mention that we just announced in early April that we did receive our first commercial coverage with Express Scripts. Express Scripts, that contract delivered quality payer coverage. We describe quality payer coverage in terms of a bucket of utilization management techniques in the range of really very simple prior auth to label, no extra onerous paperwork surrounding that prior authorization. We're familiar and have discussed quantity limits with payers in the form of, really, payers want to make sure that it is the drug that will be used a handful of times per year. If we're planning on five-10 uses per year, they just want to make sure it's not 50 uses the year. We accept quantity limits. Not saying that Express Scripts contract had those in it, but we define that bucket of quality payer coverage as such that, and I will tell you that Express Scripts didn't have all those characteristics, but fell into the quality coverage. The other thing quality coverage does for us is it enables a manageable out-of-pocket expense for the patient, right? What we can do right now, until we had Express Scripts, we had no coverage, so out-of-pockets were high. Every ability to get the drug was typically through a medical exception. The ability of that coverage, plus copay assistance, allows for that very manageable out-of-pocket expense for the patients. Our goal here is to make it accessible and affordable. We chose a retail distribution model, and we are really working quite well with, in this case, Express Scripts, and we'll work with the other payers to be able to reach coverage as soon as possible. What that means for patients is they can get it easily. What that means for healthcare providers once we get coverage is it makes it easy to prescribe. Again, not a lot of extra documentation required. Very importantly, we'd like etripamil and CARDAMYST to be prescribed and obtained by the patient in the same process that the healthcare providers prescribe the majority of their other cardiovascular products. Typical through the electronic system, showing up at the patient's favorite pharmacy, where they can pick it up in the next few days. That's our goal here. We supplement that with copay assistance. You see here our program is for patients to pay no more than $25, at least for commercial payers. Whether that's a copay card or an electronic type system like CoverMyMeds, we feel that's working quite well for those patients that get access to those cards right now. For the healthcare providers, until we achieve quality coverage across the majority of lives, we're providing patient support center to help their staffs fill out the necessary paperwork until coverage occurs. As we think about key brand performance indicators for the launch year, it's really about driving HCP awareness and adoption and establishing and maintaining broad quality access and affordability. Those are the two standards. We will be reporting out new-to-brand prescriptions on a quarterly basis. We'll provide prescription growth on week-over-week or month-over-month access. You'll be able to see that through IQVIA data or Symphony data. We will report that out on a quarterly basis. On the payer access side, we will present quarterly targeted lives covered with an emphasis on commercial. We are active in engaging Medicare plans currently. We are active in those discussions, but our expectations are coverage and decisions for coverage will impact 2027 more than they will 2026. Maybe just to recap on what we think is appealing to, and our plans for driving scripts and having scripts filled. I'll repeat, our initial sales force covers 50% of the potentially annual treated patients. We think this is a great amount of effort to be able to show that there's a market here. We'll be able to see patients seeking treatment weekly. Again, these patients are not in the office daily, like many of the other conditions that cardiologists are treating, lipid management, diabetes, et cetera. They are seen weekly. We do believe that the ability to have this top of mind when the patient's in front of them will drive scripts written. With regard to scripts filled, again, the focus is on accessibility through retail distribution. We don't want to make it hard for these patients to get access to the drug. We've provided fit-for-purpose HCP and patient support programs, and we have no expectation of any branded competition in the near term. Now I'm going to switch over a little bit to the next indication under our development program, which, as I mentioned earlier, is atrial fibrillation with rapid ventricular rate. We shorthand it AFib-RVR. I'm sure most of the audience has heard of atrial fibrillation. Compared to the 2 million patients with PSVT, atrial fibrillation is really a deluge of patients hitting the system as the population ages. Current estimates are 10 million patients with atrial fibrillation. It generates a lot of healthcare utilization, a lot of emergency department visits. Our best expectation is that that population results in about 30%-40% of the subpopulation having events of AFib with rapid rate that are frequent enough and burdensome enough where the patient will want to manage those events with some frequency with a drug like etripamil, should we be able to get it to the market. Again, from a target addressable market size, maybe three-four times what we think about the size for PSVT. Maybe I'll just give a refresher on the phase II data. This is a picture of the phase II trial design for etripamil in our AFib-RVR program. In this study, we did it in the emergency department. Patients came into the emergency department having been in atrial fibrillation for at least an hour with a ventricular rate that's elevated. We describe that as anything above 110 beats per minute. The average patient was in the 130 range. We put on an ECG monitor. We provided double-blind randomized drug, a single dose of etripamil at 70 mg or placebo randomized 1/1. We had the ECG monitor on for a few hours, six hours of remote monitoring. However, the primary endpoint was within the first 60 minutes. What we were looking for is the maximum reduction in ventricular rate over that 60-minute period. We actually had the objective of it being at least a 20 beat per minute difference in that max reduction compared to placebo. Again, I'll remind the audience that IV calcium channel blockers like verapamil and diltiazem are approved for two indications. One is for breaking PSVT in the emergency department. Second is for rapid reduction of ventricular rate for those patients in AFib-RVR. We modeled this off of trying to deliver what verapamil and diltiazem can deliver in their labels. Very importantly, secondary endpoints were how quickly we reduced the ventricular rate, like an IV would, and how long it would last. What you see on this slide is really the primary endpoint of what happens to the ventricular rate in that trial. What you're looking at is the change from baseline in ventricular rate, placebo in gray, the drug group, the single 70 mg dose of etripamil in purple. You see that the rate changed or reduced by about 35 beats per minute on that little table on the right, compared to five beats per minute in the placebo group over that one hour. That was the max reduction. That difference was about a 30 beat per minute difference. Again, we powered it to show a 20 beat per minute difference, highly statistically significant that you see there with the p-value. The other things you'll notice from the graph is that the drug started working very quickly. Within five minutes, we saw about a 20-25 beat per minute drop in the drug group. It neared out at around between 10 and 15 minutes. Very importantly, you see that effect lasting out the full hour. What's not shown on this table or this graph, but shown in other graphs that we've presented, is that that rate actually stayed down well over three hours, and that really the things that draw the groups together is the placebo group eventually came down. As in the emergency department, they were able to intervene after that hour with other medications. It is a little bit confounded after the 60 minutes. Bottom line, we saw a very rapid reduction in rate of 35 beats per minute compared to five on the placebo group. We saw it happen quickly, and we saw it last. All great attributes to be able to take the drug into the phase III trials. This is the design of the phase III trial for AFib-RVR. Again, we have the potential to deliver an approval should a single study approval work here via the sNDA pathway. We've discussed this with the FDA. We have confidence in the study, and it looks a lot like our SVT studies in the phase III at-home setting. Like the SVT studies, we will send patients home. These are patients that are already diagnosed with AFib-RVR and have a history of these events. We'll send them home with double-blind randomized drug, etripamil or placebo. We'll use the repeat dose regimen that we have approved for SVT. This regimen involves the patient taking a dose of drug, and that if they don't feel relief within 10 or 15 minutes, they'll dose themselves again. These are all symptom-prompted dosing. While they'll have an ECG on them for the primary endpoint of seeing the ventricular rate reduction, they're not prompted by that ECG. That's just running in the background, if you will. The primary endpoint of this study is that ventricular rate reduction within 30 minutes. We're hoping to see something similar that we saw in the phase II trial. Very importantly, we also have an important secondary endpoint, which is symptom relief as measured by a patient-reported outcome measure. This is necessary for approval as defined by the FDA, and that's really what we're powering this study to show. The study is coincidentally sized to be very much like our PSVT programs, 150-200 total events, powering of 90% with a p-value of less than 0.05. 0.05 is what delivers that. Operationally, we're very ready to start. We're just starting to re-engage sites and engage which sites and which countries we'll be running the study in. We were just wanting to make sure we focused on the commercial launch of CARDAMYST first before we invest significant dollars in this study. We'll expect to do that at a future date. Last slide is on the financials. As we reported in March, a $200 million pro forma cash. We think we're well-positioned to launch CARDAMYST in PSVT. We've guided that this cash should deliver runway into late 2027. What you can also see there is the equity table as of the end of the year. With that, I'll say thank you, and really open up for any questions. Great. Thanks very much, Joe. I really appreciate that great presentation there. Maybe just to get us kicked off, obviously, CARDAMYST is on the market now for coming up on two months or so. Maybe going back a little bit, can you start with what the patient journey looks like for these patients with PSVT? Where's kind of the major unmet need, and maybe walk us through again how CARDAMYST addresses that? What's the current standard of care? How are they being treated now, and how is that then being improved with CARDAMYST? Yeah. John, these patients, they have a long journey, actually, just to get to the diagnosis. These events, while they're very problematic, think about your heart racing. You come into a doctor short of breath, and they put an ECG on you, and sometimes that ECG is normal. Because it's paroxysmal, these events come on quickly, but they can actually self-resolve quickly. The journey to diagnosis is arduous for many patients. The average is three years. We feel that with the advent of wearable devices, this will be made much better, and there's just greater awareness of heart health in women. It's been an ongoing initiative, with American Heart and many others, and which we're very proud to help support with a drug like CARDAMYST. I forgot to mention that it does skew to more women, with 65% of the population being women. With regard to what's available to them now, I did focus on what's available to them in an event. It's really a vagal maneuver, and we saw this is a bearing down procedure where you try to break the tachycardia. We saw in our trials a success rate of that maneuver in the range of 5% or 6%, very low. When that didn't work, they dosed themselves with study drug. There are other options available to them, whether they be off-label use of oral medications. Many physicians use these. We've heard from thousands of physicians that there's not great data behind this. It's based on anecdotal trial and error with these oral drugs. The PK is just not there to provide enough AV nodal impact to really do a good job. They do it because they want to offer something. These patients are really in need of something in the moment. What we're hearing from physicians is, why would I not want to use a drug that has robust data for this very purpose? The other option, just to be fair, is these patients could opt for things like catheter ablations, or they're on background oral medications. These are more preventative procedures or drug use, again, off-label. I'll note that two-thirds of the patients in our clinical trials were on background, either beta blockers or calcium channel blockers, and obviously still had events and treated with study drug. It tells you that either they're somewhat effective, but certainly not effective enough to be able to deliver. What we really would want is to keep patients out of the emergency department altogether. Mm-hmm. You just mentioned at the end there, so many of these types of patients are on calcium channel blockers and beta blockers. With a prescription of CARDAMYST, are they staying on those background therapies and using CARDAMYST as a more acute-based treatment? We've heard two different use cases for CARDAMYST, either on top of those background therapies, and we're proud to have that data to show physicians that it is safe to do that, or for patients that don't really like the tolerability effects of chronic calcium channel blockers or beta blockers, there's the potential to remove those because now you have less of a fear, if you will, of when you're in an event, you have something there for it. It depends a little bit, John. If they're using it just for SVT and only for SVT, it's a younger patient. That's an option. If they're using calcium channel blockers for blood pressure control, then they would stay on it and use CARDAMYST on top of it. It's a little bit of a nuanced answer. The beauty for CARDAMYST, in our view, is that it could be used on top of or in place of or as a patient waits for an ablation procedure, another use case. There's really a multitude of use cases for CARDAMYST, and it just depends on the physician that you're in front of as to which one will be used. Great. Commercially, so I won't bug you too much because there's going to be earnings coming out, I'm sure, next month, and you've had a very limited time with the product on the market. You mentioned 60 reps targeting 10,000 key physicians. I believe that covers roughly 25% of the market. Are these 60 reps now fully trained and out in the field, or is this more of a phase-in kind of situation over the next few months? Yeah. I will correct you a little bit. The 60 reps should call on 50% of the prescribing potential of people. Oh, okay. That are in the market this year. Mm-hmm. 25% overall, though, 25% of the 2 million. Mm-hmm. They are fully trained and in the field as of the H2 of February. A big question for us was, hey, new company coming to the market. Remember, you have to get access into these offices first and foremost, right? Mm-hmm. What we are learning is that these offices, more and more practices are coming together, so you're able to call on the healthcare providers. We do a full office call. That means educating the nurse practitioners and physicians' assistants. It involves providing the copay cards and assistance to those experts and office managers who are making those calls on behalf of the patient to get them access to the drug. It is a full detail for the whole office. We're able to get in. That's a great sign right out of the gate. We did report that just when we had our last earnings call, even though it was reporting back on 2025, we reported at that time, we were about a month in, 150 prescriptions within that month, very importantly, written by 100 different prescribers. We're really hoping to get and wanting to continue to get breadth of prescribing with the idea that, like any new launch, prescribing good experience will enable more prescribing. The breadth is really important for us. Right, and then the depth comes along with that as they get more familiar and experienced with the product. From a payer perspective, so you mentioned you just got your first commercial program on board. Is most of the focus upfront on commercial over Medicare? You mentioned Medicare more later in 2027. Is most of the patient base under commercial coverage? The patient base is, it's generally thought of a young woman's condition, but the claims data tell us about 50/50, about half is under 65, half over. You would think half commercial, half Medicare. It's not that Medicare is not important, it just takes longer. We see Medicare coming on in 2027 is a little bit more inflection for later into 2027. Our focus is clearly on commercial this year for two reasons. One is we feel like we can get it sooner than Medicare. Medicare just has these timetables that while we're working with them now, their budgets are set for 2026. They're really talking about entry in 2027. Commercial can do that sooner, as was seen with Express Scripts, and with commercial, we have the ability to pay down the patient to $25. We've been very clear with investors we're willing to do that with the idea of it's important to get patient starts. This drug has done very well in the clinic. Patients that experience it want more of it, and we think when physicians see that, they'll be more inclined to prescribe for future patients. Great. We are coming up on time in just about a minute now. Maybe any last thoughts? Any things we might have missed or I didn't touch on as deep as you wanted to? Anything that might be misunderstood by investors or underappreciated by the Street about CARDAMYST or even your AFib program that's entering phase III trial soon? Yeah. No, John, I think it's a pretty simple story. I think what I'd like to double down on is we feel like the 60 sales representatives and the commercial effort that is there, we can prove this market, and it enables we have enough runway to get deep into 2027, gives us nice line of sight into break-even down the road. We don't talk about when we'll get there, but certainly line of sight to break-even is in our expectations. The combination of the runway with that expectation, we would really like investors to understand. I think that's a little bit more of an added piece that we didn't cover in the presentation. Great. Well, Joe and team, it was great to have you with us today here at our healthcare conference. We greatly look forward to keeping track of the Milestone story moving forward with commercial updates and continuing clinical progress. Thank you very much for your time. Thank you, John.